It is already known that a significant fraction of ccRCC cases remain resistant to HIF2α-inhibitor treatment [12,13,14], highlighting the importance of identifying additional therapeutic vulnerabilities in ccRCC. Here, EPAS1 is linked to nonpapillary renal cell carcinoma.